Answers are grounded in this paper and cite their sources.
Among older adults, PCV13 was effective in preventing vaccine-type pneumococcal, bacteremic, and nonbacteremic community-acquired pneumonia and vaccine-type invasive pneumococcal disease but not in preventing community-acquired pneumonia from any cause. (Funded by Pfizer; CAPITA ClinicalTrials.gov number NCT00744263.).
No takes yet. Share an insight, caveat, or question.
Bonten et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: